Is there any cumulative dose for trastuzumab?

Mutlu H., COŞKUN H. Ş.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.21, sa.6, ss.468-470, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 6
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1177/1078155214538686
  • Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.468-470
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Trastuzumab is one of the most important agents that target human epidermal growth factor receptor 2, but its cardiotoxic effect limits to use it. The mechanism of cardiac dysfunction-related trastuzumab is still unclear. In literature, there is no definite information about the cumulative dose of trastuzumab for cardiotoxicity. In presented case, we reported a breast cancer patient who has been receiving long-term trastuzumab. We have not found any cardiac problems for duration of over four years. According to our case and literature review, we may say that trastuzumab is safely used with periodically echocardiographic control in patients with breast cancer.